Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2/3 Open-Label Trial to Evaluate Enoblituzumab in Combination With MGA012 or MGD013 in the First-Line Treatment of Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

Next Previous
Search
Trial Profile

A Phase 2/3 Open-Label Trial to Evaluate Enoblituzumab in Combination With MGA012 or MGD013 in the First-Line Treatment of Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

Status: Withdrawn prior to enrolment
Phase of Trial: Phase II/III

Latest Information Update: 09 Feb 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Enoblituzumab (Primary) ; Retifanlimab (Primary) ; Tebotelimab (Primary)
  • Indications Head and neck cancer; Squamous cell cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors MacroGenics

    • Most Recent Events

    • 09 Oct 2020 Number of arms changed from 4 to 2. Experimental Arm 3 and Active Comparator: Control Arm has been removed. Study design changed from Factorial Assignment to Parallel Assignment. Allocation changed from Randomized to Non-Randomized. Drug MGD013 added. Pembrolizumab and Chemotherapeutic Combinations (carboplatin or cisplatin plus 5-fluorouracil) has been removed from study protocol.
    • 09 Oct 2020 Planned End Date changed from 1 Oct 2025 to 1 Oct 2022.
    • 09 Oct 2020 Planned primary completion date changed from 1 Oct 2025 to 1 Oct 2020.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top